Kalaris Therapeutics, Inc. cotiza a 2.26 USD y tiene una capitalización bursátil de $54M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.46 | $-0.44 | $-0.64 | $-0.61 |
| Estimado | $-0.52 | $-0.55 | $-0.61 | $-0.52 |
| Sorpresa | +11.5% | +20.0% | -4.9% | -17.3% |
| Métrica | KLRS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -55.1% | -40.4% | -14.7% |
| ROA | -35.7% | -32.0% | -3.7% |
| Current Ratio | 12.23 | 2.84 | +9.39 |
| Debt / Equity | — | 0.28 | — |